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Kathryn B. Garber1,*Out of the Ordinary
Genetic testing decisions are often based on a comparison
of a patient to the classic presentation of a mutation. Does
the patient have the appropriate family history? How well
do they match the list of expected phenotypes? Which
genes are most likely to be mutated? We have already
seen with comparative genome hybridization arrays that
the use of less-biased approaches to genetic diagnosis can
broaden the phenotype associated with certain genetic
disorders and increase the diagnostic yield in certain
classes of patients. Even though it is in its infancy, clinical
use of whole genome sequencing is likely to have a similar
effect, as illustrated in two recent JAMA papers. In both
cases, known genetic defects were uncovered, so it is not
that the relevant mutations could not have been found
via conventional techniques. However, wading through
the candidates gene-by-gene and using conventional
guidelines would probably have meant these atypical situ-
ations would have gone unidentified. In one paper, by Link
et al., a woman with early onset breast and ovarian cancer
and with no family history of cancer was found to have
a presumably de novo mutation in TP53. Although she
had been tested for mutations in BRCA1 and 2, she did
not meet the criteria for Li-Fraumeni syndrome and had
not been offered TP53 mutation analysis. The diagnosis
of Li-Fraumeni syndrome in this woman has serious impli-
cations for cancer risks to her children. In another, by
Welch et al., whole-genome sequencing was completed
on a leukemia patient within 7 weeks and resulted in a
drastic change in patient management. The woman pre-
sented with what appeared to be acute promyelocytic
leukemia (APL), which is often successfully treated with
chemotherapy plus all-trans retinoic acid when the disease
is due to chromosome translocations that lead to gene
fusions involving RARA. Standard cytogenetic analysis
indicated a poor prognosis; although the leukemic cells
had a complicated series of chromosome rearrangements,
they lacked the standard RARA fusion. She was thus
referred for allogeneic stem cell transplantation. Before
this was performed, whole-genome sequencing of her
tumor sample identified an unusual insertion event in
RARA that led to a classic APL-causing fusion gene. As a
result, the patient received all-trans retinoic acid instead
of a stem cell transplant and has a much better prognosis
than originally believed. Although at ~$20,000 per
genome whole-genome sequencing is still far from routine1Department of Human Genetics, Emory University School of Medicine, Atlan
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Link et al. JAMA 305: 1568–1576.
Welch et al. JAMA 305: 1577–1584.
Nature and Nurture in Lung Disease
Although there are familial forms of pulmonary fibrosis,
this disorder of lung scarring is a complex trait, and the
known genetic underpinnings account for a minority of
cases. Seibold et al. recently used linkage analysis followed
by association studies to uncover a new type of protein
that contributes to pulmonary fibrosis, a component of
the bronchial mucous. The genetic variant associated
with pulmonary fibrosis is upstream ofMUC5B and is asso-
ciated with increased expression of the gene in control
individuals. The fact that this increased mucin expression
might contribute to disease pathogenesis is supported by
the finding that MUC5B is overexpressed in individuals
with idiopathic pulmonary fibrosis regardless of their
genotype at this SNP, and dense accumulations of
MUC5B protein can be seen in the bronchi of these indi-
viduals. Although genetic and environmental factors
have to come together to yield lung disease, some affected
people might have a genetic predisposition to overproduc-
tion of this mucin, whereas in others the environmental
contribution might yield the same result.
Seibold et al. NEJM 364: 1503–1512.
This Story Gets Cilia and Cilia
Thenumberof genes anddisorders thatbelong to the ciliop-
athy class seems ever-increasing and serves as a model for
studying gene-gene interactions in the contribution to
disease. A recent paper adds more data to the ciliopathy
story. Although the fetal hydrolethalus and acrocallosal
syndromes were suspected to be ciliopathies based on
phenotype, which in both disorders includes polydactyly,
abnormalities of the brain, and cleft palate, it was not until
the work by Putoux et al. that this connection was ce-
mented. SNP arrays in a consanguineous family affected
by fetal hydrolethalus identified a region of homozygosity
on the long arm of chromosome 15 in affected fetuses.
The relevant gene, KIF7, is a cilia protein that was found
to be mutated in this family as well as in a series of families
affected by acrocallosal syndrome. In tissue from affected
individuals, many direct and secondary targets of GLI tran-
scription factors are upregulated, a finding that fits with theta, GA 30322, USA
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role of KIF7 in Hedgehog signaling. Although homozygous
mutations in KIF7 cause these rare syndromes, additional
data implicate heterozygous KIF7 variation in the develop-
ment of other ciliopathies. In a sample of 130 individuals
with ciliopathies caused bymutations in other genes, hypo-
morphic missense changes in KIF7 were significantly en-
riched compared to controls, suggesting thatKIF7 variation
exacerbates the phenotype caused by other ciliary defects.
Putoux et al. Nature Genetics. Published online May 8, 2011.
10.1038/ng.826.
Fostering Tolerance
I imagine a lot of us were taught that the sickle cell trait
protects against malaria because it makes red blood cells
fragile, thereby inhibiting replication of the parasite. Ferre-
ira et al. recently proposed a completely new model, based
on experiments in mice expressing human hemoglobin, to
explain the protective effect of the sickle cell allele. It turns
out, at least in this mouse model of severe malaria, that the
protection is not a result of reduced parasite load. Instead,
the HbS allele fosters immune tolerance, thereby lessening
the risk of cerebral malaria, an immunologically-mediated,
severe complication of the infection. More than a single
factor contributes to this tolerance. For one, a low, but
elevated, level of free heme from HbS induces expression
of the heme oxygenase-1 (HO-1) via the Nrf2 transcription
factor. HO-1 catabolizes the free heme to protect against its
cytotoxicity, thereby preventing tissue damage. This reac-
tion also produces carbon monoxide, which in turn
prevents further release of free heme as well as having
anti-inflammatory properties. Second, in the brain, HO-1
inhibits expression of chemokines that contribute to the
pathogenesis of cerebral malaria. Finally, through amecha-
nism that does not involve HO-1, the HbS allele prevents
expansion of CD8þT cells that promote development of682 The American Journal of Human Genetics 88, 681–683, June 10,cerebral malaria. Thus, it appears that the sickle cell trait
might not increase malaria survival by reining in the para-
site as much as it reins in the host response to reduce the
severe complications of the infection.
Ferreira et al. Cell 145: 398–409.
Hit Me One Time. Hit Me Two Times
How do you sort through the reams of sequence data that
you get from a whole-genome or whole-exome sequence
project?O’Roak et al. decided to focus on de novomutation
events through use of parent-child trios in the hopes of ex-
plaining sporadic cases of autism. In 20 such trios, they
found 11 de novo events that were predicted to alter the en-
coded protein, a manageable number to wade through. Of
these, four are identified as potentially causative. These
mutations were found in GRIN2B, FOXP1, SCN1A, and
LAMC3. Seems pretty cut and dried, right? The parents do
not have autism, the kids do, and there are new mutations
in genes that make sense for the autism phenotype. Yet,
the authors did not stop there. They found that two of the
four probands with putative causal de novo mutations
also had inherited mutations that likely contributed to
the phenotype. One possesses a de novo missense change
in SCN1A in conjunction with a maternally inherited dele-
tion at 15q11.2 that is known to increase risk of epilepsy
and schizophrenia. Another has a truncating FOXP1muta-
tion as well as an inherited, deleterious mutation in
CNTNAP2, a gene that is negatively regulated by FOXP1.
The truncated form of FOXP1 does not do this as well as it
should, yielding increased expression of CNTNAP2. This
lack of downregulation could exacerbate the effect of the
CNTNAP2 mutation, leading the authors to propose that
multiple ‘‘hits’’ might cause some cases of sporadic autism.
O’Roak et al. Nature Genetics. Published online May 15,
2011. 10.1038/ng.835.This Month in Our Sister JournalsHigh-Throughput Approach to FMR1 Analysis for Use
in Both Sexes
The broad size range for the fragile-X-syndrome-related
CGG repeat in FMR1 makes it a challenge to develop a
single high-throughput diagnostic technique that will
size repeats across this range and simultaneously assess
their methylation status. Chen et al. recently developed
a two-color PCR-based approach that improves the ability
to do just that. In their approach, two aliquots of a
genomic sample are prepared, and one is treated with
a methylation-sensitive restriction enzyme. Each is then
amplified using a fluorescent primer, and the two prod-
ucts are combined and analyzed through capillary elec-
trophoresis using the two appropriate color channels.Methylated alleles are resistant to digestion, so the peak
size for each allele can be compared in the digested and
control reactions to measure the methylation fraction
for each allele. Results based on this technique agree
with those from Southern blot analysis for several tested
cell lines and clinical samples, representing a range of
allele sizes. Unlike some of the previously-proposed
PCR-based techniques for FMR1 analysis, this approach
can be used in both males and females, and it yielded
an unexpected finding in females with premutation-sized
alleles; of 18 such samples, 15 exhibited size mosaicism
for the premutation allele as well as a skewed methyla-
tion pattern at the repeat. Whether and how this ties in
to premutation instability and/or to the penetrance of2011
FMR1 premutation-associated phenotypes remains to be
discovered.
Chen et al. Genetics in Medicine. Published online March 25,
2011. 10.1097/GIM.0b013e31820a780f.
Fitness Test for Cancer Mutations
In order to better understand carcinogenesis, much effort
has been directed recently at genomic analysis of cancers
with comparisons to the constitutional genome of the
affected individual. A key to the interpretation of these
data is the determination of the ‘‘driver’’ mutations from
the ‘‘passenger’’ mutations. In other words, which of the
mutations actually contributed to the development ofThe Amethe cancer and which are simply along for the ride? Fischer
et al. recently published an analytic method to make this
distinction that uses germline fitness to assess mutations
and target loci. Their analysis of cancer mutations in
a set of kinase genes is used to assess their approach.
They argue that this type of evolutionary-theory-based
analysis will help to uncover novel cancer genes. They
also find evidence that somaticmutation of putative tumor
suppressor genes is generally more deleterious to fitness
than is oncogene mutation, hinting that tumor suppressor
mutations are more likely to drive cancer development.
Fischer et al. Genetics. Published online March 24, 2011.
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